Can Dayvigo (lemborexant) treat sleep apnea?
Dayvigo (lemborexant) is approved to treat insomnia. It is not an established treatment for obstructive sleep apnea (OSA) or central sleep apnea (CSA), and it should not be used as a substitute for standard sleep apnea care such as CPAP (for OSA) or other apnea-specific therapies.
What do clinicians typically use for sleep apnea instead?
For most patients with obstructive sleep apnea, the mainstay treatment is positive airway pressure therapy (commonly CPAP). Other options may include oral appliances, weight management, and procedures depending on the cause and severity. Medication choices for sleep apnea are usually aimed at specific apnea types and patient situations rather than insomnia alone.
Is it ever used in someone who has both insomnia and sleep apnea?
Some patients with sleep apnea also have insomnia. In those cases, a clinician may consider an insomnia medication to help with sleep maintenance or onset, but the patient’s apnea must still be actively managed. In practice, that means ensuring the apnea is treated (for example, using CPAP if prescribed) before or alongside any insomnia therapy.
What’s the main risk if sleep apnea isn’t controlled?
The main concern is that untreated sleep apnea can still cause disrupted breathing during sleep and ongoing drops in oxygen. An insomnia medication does not address the airway or respiratory control problem driving the apneas, so insomnia symptoms could improve while apnea remains inadequately treated, which can leave health risks unchanged.
What should a patient ask their doctor before taking Dayvigo?
Patients with known or suspected sleep apnea should ask:
- Whether their apnea is obstructive or central, and how severe it is
- Whether they should be on CPAP or another apnea-specific treatment first
- How to monitor for daytime sleepiness or worsening breathing symptoms
- Whether their other medications or alcohol use affect breathing during sleep
Quick check
If the question is about someone with a confirmed sleep apnea diagnosis: Dayvigo may be considered only for insomnia symptoms, and only with the sleep apnea itself being treated appropriately. If the question is about someone who hasn’t been diagnosed yet, new insomnia symptoms should not be assumed to be “just insomnia” without evaluating for sleep apnea.
Sources: The provided information does not include Dayvigo’s prescribing details or safety/labeling language for sleep apnea, so I can’t quote the label-specific guidance from here. If you share whether the patient has OSA vs CSA and whether they use CPAP, I can tailor the answer to the most relevant clinical considerations.